Marshall Wace’s Crescent Biopharma CBIO Stock Holding History

Marshall Wace’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.86M	Buy	214,300 +13,520	+7%	+$264K	﹤0.01%	1499
2026 Q1	$3.69M	Buy	200,780 +178,954	+820%	+$2.05M	﹤0.01%	1454
2025 Q4	$259K	Sell	21,826 -21,868	-50%	-$279K	﹤0.01%	2505
2025 Q3	$520K	Buy	+43,694	New	+$580K	﹤0.01%	2217
2024 Q2	–	Sell	-2,175	Closed	-$653K	–	2694
2024 Q1	$653K	Buy	2,175 +2,046	+1,586%	+$611K	﹤0.01%	1830
2023 Q4	$30.4K	Buy	+129	New	+$20.1K	﹤0.01%	2096
2023 Q3	–	Sell	-1,424	Closed	-$248K	–	2383
2023 Q2	$248K	Sell	1,424 -739	-34%	-$124K	﹤0.01%	2191
2023 Q1	$273K	Buy	2,163 +74	+4%	+$16.7K	﹤0.01%	2327
2022 Q4	$633K	Buy	+2,089	New	+$308K	﹤0.01%	2282
2019 Q1	–	Sell	-1,583	Closed	-$1.5M	–	1843
2018 Q4	$1.5M	Buy	+1,583	New	+$1.9M	0.02%	800

Other funds holding CBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace's CBIO Position: Q2 2026 in Review

Marshall Wace increased its Crescent Biopharma (CBIO) stake by 6.7% in Q2 2026, buying an estimated $264K and bringing the position to 214,300 shares worth $3.86M. The position accounts for ﹤0.01% of the portfolio, ranked #1499.

Marshall Wace first reported a position in CBIO in Q4 2018 and has held it in 10 quarters since. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

Marshall Wace held 214,300 shares of Crescent Biopharma worth $3.86M as of Q2 2026.
Marshall Wace bought 13,520 Crescent Biopharma shares in Q2 2026, an estimated $264K.
Crescent Biopharma made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1499 holding.
Marshall Wace first reported a position in Crescent Biopharma in Q4 2018 and has held it in 10 quarters since.
82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.